-
1
-
-
84862557038
-
-
USRDS TUSRDS. Annual Data Report. Bethesda: The National Institutes of Diabetes and Digestive and Kidney Diseases
-
USRDS TUSRDS. Annual Data Report. Bethesda: The National Institutes of Diabetes and Digestive and Kidney Diseases; 2005.
-
(2005)
-
-
-
2
-
-
0141819203
-
Proteinuria and other markers of chronic kidney disease: A position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
-
DOI 10.1016/S0272-6386(03)00826-6
-
Eknoyan G,Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: A position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis. 2003;42:617-22. (Pubitemid 37187362)
-
(2003)
American Journal of Kidney Diseases
, vol.42
, Issue.4
, pp. 617-622
-
-
Eknoyan, G.1
Hostetter, T.2
Bakris, G.L.3
Hebert, L.4
Levey, A.S.5
Parving, H.-H.6
Steffes, M.W.7
Toto, R.8
Willis, K.9
-
3
-
-
20844448302
-
Diabetic nephropathy: Linking histology, cell biology, and genetics
-
Adler S. Diabetic nephropathy: Linking histology, cell biology, and genetics. Kidney Int. 2004;66:2095-106.
-
(2004)
Kidney Int
, vol.66
, pp. 2095-106
-
-
Adler, S.1
-
4
-
-
0021236983
-
Predicting diabetic nephropathy in insulin-dependent patients
-
Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med. 1984;311:89-93. (Pubitemid 14084080)
-
(1984)
New England Journal of Medicine
, vol.311
, Issue.2
, pp. 89-93
-
-
Mogensen, C.E.1
Christensen, C.K.2
-
5
-
-
0033850165
-
The need for early predictors of diabetic nephropathy risk: Is albumin excretion rate sufficient?
-
Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: Is albumin excretion rate sufficient? Diabetes. 2000;49:1399-408.
-
(2000)
Diabetes
, vol.49
, pp. 1399-408
-
-
Caramori, M.L.1
Fioretto, P.2
Mauer, M.3
-
6
-
-
33645450441
-
Enhancing the predictive value of urinary albumin for diabetic nephropathy
-
Caramori ML, Fioretto P, Mauer M. Enhancing the predictive value of urinary albumin for diabetic nephropathy. J Am Soc Nephrol. 2006;17:339-52.
-
(2006)
J Am Soc Nephrol
, vol.17
, pp. 339-52
-
-
Caramori, M.L.1
Fioretto, P.2
Mauer, M.3
-
7
-
-
0345505677
-
Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: An indicator of more advanced glomerular lesions
-
DOI 10.2337/diabetes.52.4.1036
-
Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: An indicator of more advanced glomerular lesions. Diabetes. 2003;52:1036-40. (Pubitemid 36384275)
-
(2003)
Diabetes
, vol.52
, Issue.4
, pp. 1036-1040
-
-
Caramori, M.L.1
Fioretto, P.2
Mauer, M.3
-
8
-
-
33750591713
-
Persistent renal hypertrophy and faster decline of glomerular filtration rate precede the development of microalbuminuria in type 1 diabetes
-
DOI 10.2337/db06-0592
-
Zerbini G, Bonfanti R, Meschi F, et al. Persistent renal hypertrophy and faster decline of glomerular filtration rate precede the development of microalbuminuria in type 1 diabetes. Diabetes. 2006;55:2620-5. (Pubitemid 44871164)
-
(2006)
Diabetes
, vol.55
, Issue.9
, pp. 2620-2625
-
-
Zerbini, G.1
Bonfanti, R.2
Meschi, F.3
Bognetti, E.4
Paesano, P.L.5
Gianolli, L.6
Querques, M.7
Maestroni, A.8
Calori, G.9
Del Maschio, A.10
Fazio, F.11
Luzi, L.12
Chiumello, G.13
-
9
-
-
0031959237
-
Expression of connective tissue growth factor in human renal fibrosis
-
DOI 10.1111/j.1523-1755.1998.00820.x
-
Ito Y, Aten J, Bende RJ, et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. 1998;53:853-61. (Pubitemid 28155657)
-
(1998)
Kidney International
, vol.53
, Issue.4
, pp. 853-861
-
-
Ito, Y.1
Aten, J.2
Bende, R.J.3
Oemar, B.S.4
Rabelink, T.J.5
Weening, J.J.6
Goldschmeding, R.7
-
10
-
-
33644875787
-
Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy
-
Nguyen TQ, Tarnow L, Andersen S, et al. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2006;29:83-8. (Pubitemid 44033436)
-
(2006)
Diabetes Care
, vol.29
, Issue.1
, pp. 83-88
-
-
Nguyen, T.Q.1
Tarnow, L.2
Andersen, S.3
Hovind, P.4
Parving, H.-H.5
Goldschmeding, R.6
Van Nieuwenhoven, F.A.7
-
11
-
-
33845501691
-
Transforming growth Factor-β in human diabetic nephropathy: Effects of ACE inhibition
-
DOI 10.2337/dc06-0911
-
Langham RG, Kelly DJ, Gow RM, et al. Transforming growth factorbeta in human diabetic nephropathy: Effects of ACE inhibition. Diabetes Care. 2006;29:2670-5. (Pubitemid 44912197)
-
(2006)
Diabetes Care
, vol.29
, Issue.12
, pp. 2670-2675
-
-
Langham, R.G.1
Kelly, D.J.2
Gow, R.M.3
Zhang, Y.4
Cordonnier, D.J.5
Pinel, N.6
Zaoui, P.7
Gilbert, R.E.8
-
12
-
-
0141674965
-
Urinary and renal interstitial concentrations of TNF-α increase prior to the rise in albuminuria in diabetic rats
-
DOI 10.1046/j.1523-1755.2003.00237.x
-
Kalantarinia K, Awad AS, Siragy HM. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int. 2003;64:1208-13. (Pubitemid 37153785)
-
(2003)
Kidney International
, vol.64
, Issue.4
, pp. 1208-1213
-
-
Kalantarinia, K.1
Awad, A.S.2
Siragy, H.M.3
-
13
-
-
0033833789
-
Urinary excretion of podocytes in patients with diabetic nephropathy
-
Nakamura T, Ushiyama C, Suzuki S, et al. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant. 2000;15:1379-83.
-
(2000)
Nephrol Dial Transplant
, vol.15
, pp. 1379-83
-
-
Nakamura, T.1
Ushiyama, C.2
Suzuki, S.3
-
14
-
-
66849091695
-
Neutrophil Gelatinase-Associated Lipocalin (NGAL) and progression of chronic kidney disease
-
Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:337-44.
-
(2009)
Clin J Am Soc Nephrol
, vol.4
, pp. 337-44
-
-
Bolignano, D.1
Lacquaniti, A.2
Coppolino, G.3
-
15
-
-
79551536740
-
Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetylbeta-D-glucosaminidase
-
Vaidya VS, Niewczas MA, Ficociello LH, et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetylbeta-D- glucosaminidase. Kidney Int. 2011;79:464-70.
-
(2011)
Kidney Int
, vol.79
, pp. 464-70
-
-
Vaidya, V.S.1
Niewczas, M.A.2
Ficociello, L.H.3
-
16
-
-
0027370108
-
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
-
The Diabetes Control and Complications Trial Research Group
-
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-986.
-
(1993)
N Engl J Med
, vol.329
, pp. 977-986
-
-
-
18
-
-
0142087597
-
Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study
-
Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159-2167.
-
(2003)
JAMA
, vol.290
, pp. 2159-2167
-
-
-
19
-
-
29144453326
-
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
-
DOI 10.1056/NEJMoa052187
-
Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-53. (Pubitemid 41817713)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.25
, pp. 2643-2653
-
-
Nathan, D.M.1
Cleary, P.A.2
Backlund, J.-Y.C.3
Genuth, S.M.4
Lachin, J.M.5
Orchard, T.J.6
Raskin, P.7
Zinman, B.8
-
20
-
-
0034641568
-
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
-
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321:405-12. (Pubitemid 30609442)
-
(2000)
British Medical Journal
, vol.321
, Issue.7258
, pp. 405-412
-
-
Stratton, I.M.1
Adler, A.I.2
Neil, H.A.W.3
Matthews, D.R.4
Manley, S.E.5
Cull, C.A.6
Hadden, D.7
Turner, R.C.8
Holman, R.R.9
-
21
-
-
53749096863
-
10-year follow-up of intensive glucose control in type 2 diabetes
-
Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89.
-
(2008)
N Engl J Med
, vol.359
, pp. 1577-89
-
-
Holman, R.R.1
Paul, S.K.2
Bethel, M.A.3
-
22
-
-
0032511583
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33
-
UK Prospective Diabetes Study (UKPDS) Group
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
-
(1998)
Lancet
, vol.352
, pp. 837-853
-
-
-
23
-
-
45149133036
-
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
-
DOI 10.1056/NEJMoa0802987
-
Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-72. (Pubitemid 351831357)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.24
, pp. 2560-2572
-
-
Patel, A.1
MacMahon, S.2
Chalmers, J.3
Neal, B.4
Billot, L.5
Woodward, M.6
Marre, M.7
Cooper, M.8
Glasziou, P.9
Grobbee, D.10
Hamet, P.11
Harrap, S.12
Heller, S.13
Liu, L.14
Mancia, G.15
Mogensen, C.E.16
Pan, C.17
Poulter, N.18
Rodgers, A.19
Williams, B.20
Bompoint, S.21
De Galan, B.E.22
Joshi, R.23
Travert, F.24
more..
-
24
-
-
77955585592
-
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial
-
Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial. Lancet. 2010;376:419-30.
-
(2010)
Lancet
, vol.376
, pp. 419-30
-
-
Ismail-Beigi, F.1
Craven, T.2
Banerji, M.A.3
-
25
-
-
58149389215
-
Glucose control and vascular complications in veterans with type 2 diabetes
-
Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-39.
-
(2009)
N Engl J Med
, vol.360
, pp. 129-39
-
-
Duckworth, W.1
Abraira, C.2
Moritz, T.3
-
26
-
-
0014093712
-
Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy
-
Kelly WD, Lillehei RC, Merkel FK, et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery. 1967;61:827-37.
-
(1967)
Surgery
, vol.61
, pp. 827-37
-
-
Kelly, W.D.1
Lillehei, R.C.2
Merkel, F.K.3
-
27
-
-
0002155673
-
Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of October 2002
-
Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of October 2002. Clin Transplant. 2002;2002:41-77.
-
(2002)
Clin Transplant
, vol.2002
, pp. 41-77
-
-
Gruessner, A.C.1
Sutherland, D.E.2
-
28
-
-
19944399783
-
The beneficial effects of pancreas transplant alone on diabetic nephropathy
-
DOI 10.2337/diacare.28.6.1366
-
Coppelli A, Giannarelli R, Vistoli F, et al. The beneficial effects of pancreas transplant alone on diabetic nephropathy. Diabetes Care. 2005;28:1366-70. (Pubitemid 40756698)
-
(2005)
Diabetes Care
, vol.28
, Issue.6
, pp. 1366-1370
-
-
Coppelli, A.1
Giannarelli, R.2
Vistoli, F.3
Del Prato, S.4
Rizzo, G.5
Mosca, F.6
Boggi, U.7
Marchetti, P.8
-
29
-
-
0024334899
-
The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin-dependent diabetes
-
Bilous RW, Mauer SM, Sutherland DE, et al. The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin-dependent diabetes. N Engl J Med. 1989;321:80-5. (Pubitemid 19170396)
-
(1989)
New England Journal of Medicine
, vol.321
, Issue.2
, pp. 80-85
-
-
Bilous, R.W.1
Mauer, S.M.2
Sutherland, D.E.R.3
Najarian, J.S.4
Goetz, F.C.5
Steffes, M.W.6
-
30
-
-
0027493382
-
Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys
-
DOI 10.1016/0140-6736(93)92183-T
-
Fioretto P, Mauer SM, Bilous RW, et al. Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys. Lancet. 1993;342:1193-6. (Pubitemid 23331708)
-
(1993)
Lancet
, vol.342
, Issue.8881
, pp. 1193-1196
-
-
Fioretto, P.1
Mauer, S.M.2
Bilous, R.W.3
Goetz, F.C.4
Sutherland, D.E.R.5
Steffes, M.W.6
-
31
-
-
0032499911
-
Reversal of lesions of diabetic nephropathy after pancreas transplantation
-
DOI 10.1056/NEJM199807093390202
-
Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339:69-75. (Pubitemid 28304880)
-
(1998)
New England Journal of Medicine
, vol.339
, Issue.2
, pp. 69-75
-
-
Fioretto, P.1
Steffes, M.W.2
Sutherland, D.E.R.3
Goetz, F.C.4
Mauer, M.5
-
32
-
-
46449117004
-
The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: A decision analysis
-
Huang ES, Zhang Q, Gandra N, et al. The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: A decision analysis. Ann Intern Med. 2008;149:11-9.
-
(2008)
Ann Intern Med
, vol.149
, pp. 11-9
-
-
Huang, E.S.1
Zhang, Q.2
Gandra, N.3
-
33
-
-
0019965181
-
Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy
-
Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed). 1982;285:685-8. (Pubitemid 12051454)
-
(1982)
British Medical Journal
, vol.285
, Issue.6343
, pp. 685-688
-
-
Mogensen, C.E.1
-
34
-
-
0036190137
-
Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes
-
DOI 10.1046/j.1523-1755.2002.00213.x
-
Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086-97. (Pubitemid 34175478)
-
(2002)
Kidney International
, vol.61
, Issue.3
, pp. 1086-1097
-
-
Schrier, R.W.1
Estacio, R.O.2
Esler, A.3
Mehler, P.4
-
35
-
-
0032511580
-
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
-
UK Prospective Diabetes Study Group
-
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-713.
-
(1998)
BMJ
, vol.317
, pp. 703-713
-
-
-
36
-
-
7344263454
-
Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40
-
UK Prospective Diabetes Study Group
-
Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. BMJ. 1998;317:720-726.
-
(1998)
BMJ
, vol.317
, pp. 720-726
-
-
-
37
-
-
34548420712
-
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial
-
DOI 10.1016/S0140-6736(07)61303-8, PII S0140673607613038
-
Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007;370:829-40. (Pubitemid 47362321)
-
(2007)
Lancet
, vol.370
, Issue.9590
, pp. 829-840
-
-
Patel, A.1
-
38
-
-
65249111029
-
Lowering blood pressure reduces renal events in type 2 diabetes
-
de Galan BE, Perkovic V, Ninomiya T, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol. 2009;20:883-92.
-
(2009)
J Am Soc Nephrol
, vol.20
, pp. 883-92
-
-
De Galan, B.E.1
Perkovic, V.2
Ninomiya, T.3
-
39
-
-
0347423198
-
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
-
DOI 10.1161/01.HYP.0000107251.49515.c2
-
Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-52. (Pubitemid 37553153)
-
(2003)
Hypertension
, vol.42
, Issue.6
, pp. 1206-1252
-
-
Chobanian, A.V.1
Bakris, G.L.2
Black, H.R.3
Cushman, W.C.4
Green, L.A.5
Izzo Jr., J.L.6
Jones, D.W.7
Materson, B.J.8
Oparil, S.9
Wright Jr., J.T.10
Roccella, E.J.11
-
40
-
-
11844259382
-
Standards of medical care in diabetes
-
Standards of medical care in diabetes. Diabetes Care. 2005;28(Suppl 1):S4-S36.
-
(2005)
Diabetes Care
, vol.28
, Issue.SUPPL. 1
-
-
-
41
-
-
3042819708
-
K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease
-
K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:S1-290.
-
(2004)
Am J Kidney Dis
, vol.43
-
-
-
42
-
-
77951735232
-
Effects of intensive blood-pressure control in type 2 diabetes mellitus
-
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010.
-
(2010)
N Engl J Med
-
-
-
43
-
-
0035804277
-
Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (dash) diet
-
DOI 10.1056/NEJM200101043440101
-
Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3-10. (Pubitemid 32064838)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.1
, pp. 3-10
-
-
Sacks, F.M.1
Svetkey, L.P.2
Vollmer, W.M.3
Appel, L.J.4
Bray, G.A.5
Harsha, D.6
Obarzanek, E.7
Conlin, P.R.8
Miller III, E.R.9
Simons-Morton, D.G.10
Karanja, N.11
Lin, P.-H.12
Aickin, M.13
Most-Windhauser, M.M.14
Moore, T.J.15
Proschan, M.A.16
Cutler, J.A.17
-
44
-
-
0028867689
-
Prevention of diabetic renal disease with special reference to microalbuminuria
-
Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995;346:1080-4.
-
(1995)
Lancet
, vol.346
, pp. 1080-4
-
-
Mogensen, C.E.1
Keane, W.F.2
Bennett, P.H.3
-
45
-
-
0027049331
-
Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis
-
Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med. 1993;118:129-38.
-
(1993)
Ann Intern Med
, vol.118
, pp. 129-38
-
-
Kasiske, B.L.1
Kalil, R.S.2
Ma, J.Z.3
-
46
-
-
0029857846
-
Appropriate blood pressure control in NIDDM (ABCD) Trial
-
DOI 10.1007/s001250050629
-
Schrier RW, Estacio RO, Jeffers B. Appropriate Blood Pressure Control in NIDDM (ABCD) trial. Diabetologia. 1996;39:1646-54. (Pubitemid 26397382)
-
(1996)
Diabetologia
, vol.39
, Issue.12
, pp. 1646-1654
-
-
Schrier, R.W.1
Estacio, R.O.2
Jeffers, B.3
-
47
-
-
0032513878
-
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
-
DOI 10.1016/S0140-6736(98)04311-6
-
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-62. (Pubitemid 28269185)
-
(1998)
Lancet
, vol.351
, Issue.9118
, pp. 1755-1762
-
-
Hansson, L.1
Zanchetti, A.2
Carruthers, S.G.3
Dahlof, B.4
Elmfeldt, D.5
Julius, S.6
Menard, J.7
Rahn, K.H.8
Wedel, H.9
Westerling, S.10
-
48
-
-
0028215329
-
The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease
-
DOI 10.1056/NEJM199403313301301
-
Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control and the progression of chronic renal disease. N Engl J Med. 1994;330:877-84. (Pubitemid 24094966)
-
(1994)
New England Journal of Medicine
, vol.330
, Issue.13
, pp. 877-884
-
-
Klahr, S.1
Levey, A.S.2
Beck, G.J.3
Caggiula, A.W.4
Hunsicker, L.5
Kusek, J.W.6
Striker, G.7
-
49
-
-
0037145856
-
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial
-
DOI 10.1001/jama.288.19.2421
-
Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA. 2002;288:2421-31. (Pubitemid 35340538)
-
(2002)
Journal of the American Medical Association
, vol.288
, Issue.19
, pp. 2421-2431
-
-
Wright Jr., J.T.1
Bakris, G.2
Greene, T.3
Agodoa, L.Y.4
Appel, L.J.5
Charleston, J.6
Cheek, D.7
Douglas-Baltimore, J.G.8
Gassman, J.9
Glassock, R.10
Hebert, L.11
Jamerson, K.12
Lewis, J.13
Phillips, R.A.14
Toto, R.D.15
Middleton, J.P.16
Rostand, S.G.17
-
50
-
-
79959811620
-
Diabetes, hypertension, and outcome studies: Overview 2010
-
Nilsson PM, Cederholm J. Diabetes, hypertension, and outcome studies: Overview 2010. Diabetes Care. 2011;34(Suppl 2):S109-13.
-
(2011)
Diabetes Care
, vol.34
, Issue.SUPPL. 2
-
-
Nilsson, P.M.1
Cederholm, J.2
-
51
-
-
0037898667
-
Treatment of hypertension in adults with diabetes
-
Arauz-Pacheco C, Parrott MA, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26(Suppl 1):S80-2. (Pubitemid 36928963)
-
(2003)
Diabetes Care
, vol.26
, Issue.SUPPL. 1
-
-
Arauz-Pacheo, C.1
Parrott, M.A.2
Raskin, P.3
-
52
-
-
0038460302
-
The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNV 7 report
-
DOI 10.1001/jama.289.19.2560
-
Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289:2560-72. (Pubitemid 37430158)
-
(2003)
Journal of the American Medical Association
, vol.289
, Issue.19
, pp. 2560-2572
-
-
Chobanian, A.V.1
Bakris, G.L.2
Black, H.R.3
Cushman, W.C.4
Green, L.A.5
Izzo Jr., J.L.6
Jones, D.W.7
Materson, B.J.8
Oparil, S.9
Wright Jr., J.T.10
Roccella, E.J.11
-
53
-
-
77951735232
-
Effects of intensive blood-pressure control in type 2 diabetes mellitus
-
Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85.
-
(2010)
N Engl J Med
, vol.362
, pp. 1575-85
-
-
Cushman, W.C.1
Evans, G.W.2
Byington, R.P.3
-
54
-
-
77954374543
-
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease
-
Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61-8.
-
(2010)
JAMA
, vol.304
, pp. 61-8
-
-
Cooper-DeHoff, R.M.1
Gong, Y.2
Handberg, E.M.3
-
55
-
-
77957259177
-
Systolic blood pressure and risk of cardiovascular diseases in type 2 diabetes: An observational study from the Swedish national diabetes register
-
Cederholm J, Gudbjornsdottir S, Eliasson B, et al. Systolic blood pressure and risk of cardiovascular diseases in type 2 diabetes: An observational study from the Swedish national diabetes register. J Hypertens. 2010;28:2026-35.
-
(2010)
J Hypertens
, vol.28
, pp. 2026-35
-
-
Cederholm, J.1
Gudbjornsdottir, S.2
Eliasson, B.3
-
56
-
-
0025028032
-
Prostaglandins, angiotension II, and proteinuria
-
Dunn MJ. Prostaglandins, angiotension II, and proteinuria. Nephron. 1990;55(Suppl 1):30-7.
-
(1990)
Nephron
, vol.55
, Issue.SUPPL. 1
, pp. 30-7
-
-
Dunn, M.J.1
-
57
-
-
0027522956
-
Angiotensin-converting enzyme inhibitors in diabetic nephropathy
-
Melchior WR, Bindlish V, Jaber LA. Angiotensin-converting enzyme inhibitors in diabetic nephropathy. Ann Pharmacother. 1993;27:344-50. (Pubitemid 23086962)
-
(1993)
Annals of Pharmacotherapy
, vol.27
, Issue.3
, pp. 344-350
-
-
Melchior, W.R.1
Bindlish, V.2
Jaber, L.A.3
Martinez, M.4
Fiset, C.5
-
58
-
-
7444237666
-
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy
-
DOI 10.1056/NEJMoa042274
-
Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952-61. (Pubitemid 39447136)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.19
, pp. 1952-1961
-
-
Barnett, A.H.1
Bain, S.C.2
Bouter, P.3
Karlberg, B.4
Madsbad, S.5
Jervell, J.6
Mustonen, J.7
-
59
-
-
34548444609
-
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus
-
DOI 10.1097/HJH.0b013e328277596e, PII 0000487220070900000024
-
Hollenberg NK, Parving HH, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007;25:1921-6. (Pubitemid 47356634)
-
(2007)
Journal of Hypertension
, vol.25
, Issue.9
, pp. 1921-1926
-
-
Hollenberg, N.K.1
Parving, H.-H.2
Viberti, G.3
Remuzzi, G.4
Ritter, S.5
Zelenkofske, S.6
Kandra, A.7
Daley, W.L.8
Rocha, R.9
-
60
-
-
65249126924
-
Supramaximal dose of candesartan in proteinuric renal disease
-
Burgess E, Muirhead N, Rene de Cotret P, et al. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol. 2009;20:893-900.
-
(2009)
J Am Soc Nephrol
, vol.20
, pp. 893-900
-
-
Burgess, E.1
Muirhead, N.2
Rene De Cotret, P.3
-
61
-
-
38049139424
-
Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease
-
Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148:30-48. (Pubitemid 351688350)
-
(2008)
Annals of Internal Medicine
, vol.148
, Issue.1
, pp. 30-48
-
-
Kunz, R.1
Friedrich, C.2
Wolbers, M.3
Mann, J.F.E.4
-
62
-
-
49149087718
-
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial
-
Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-53.
-
(2008)
Lancet
, vol.372
, pp. 547-53
-
-
Mann, J.F.1
Schmieder, R.E.2
McQueen, M.3
-
63
-
-
0030908772
-
Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria
-
Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet. 1997;349:1787-1792.
-
(1997)
The EUCLID Study Group. Lancet
, vol.349
, pp. 1787-1792
-
-
-
64
-
-
0032525867
-
Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: A randomized, controlled trial
-
Ravid M, Brosh D, Levi Z, et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;128:982-8. (Pubitemid 28275174)
-
(1998)
Annals of Internal Medicine
, vol.128
, Issue.12 PART 1
, pp. 982-988
-
-
Ravid, M.1
Brosh, D.2
Levi, Z.3
Bar-Dayan, Y.4
Ravid, D.5
Rachmani, R.6
-
65
-
-
0034074955
-
Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes
-
Estacio RO, Jeffers BW, Gifford N, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(Suppl 2): B54-64. (Pubitemid 30185779)
-
(2000)
Diabetes Care
, vol.23
, Issue.SUPPL. 2
-
-
Estacio, R.O.1
Jeffers, B.W.2
Gifford, N.3
Schrier, R.W.4
-
66
-
-
0027517013
-
Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients
-
Ravid M, Savin H, Jutrin I, et al. Long-term stabilization of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118:577-81. (Pubitemid 23102690)
-
(1993)
Annals of Internal Medicine
, vol.118
, Issue.8
, pp. 577-581
-
-
Ravid, M.1
Savin, H.2
Jutrin, I.3
Bental, T.4
Katz, B.5
Lishner, M.6
-
67
-
-
0033917552
-
Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy
-
DOI 10.1046/j.1523-1755.2000.00880.x
-
Andersen S, Tarnow L, Rossing P, et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int. 2000;57:601-6. (Pubitemid 30430652)
-
(2000)
Kidney International
, vol.57
, Issue.2
, pp. 601-606
-
-
Andersen, S.1
Tarnow, L.2
Rossing, P.3
Hansen, B.V.4
Parving, H.-H.5
-
68
-
-
0035922441
-
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
-
Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9.
-
(2001)
N Engl J Med
, vol.345
, pp. 861-9
-
-
Brenner, B.M.1
Cooper, M.E.2
De Zeeuw, D.3
-
69
-
-
0035922447
-
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
-
Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60.
-
(2001)
N Engl J Med
, vol.345
, pp. 851-60
-
-
Lewis, E.J.1
Hunsicker, L.G.2
Clarke, W.R.3
-
70
-
-
0035922444
-
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
-
Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-8.
-
(2001)
N Engl J Med
, vol.345
, pp. 870-8
-
-
Parving, H.H.1
Lehnert, H.2
Brochner-Mortensen, J.3
-
71
-
-
0027517659
-
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
-
DOI 10.1056/NEJM199311113292004
-
Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-62. (Pubitemid 23335891)
-
(1993)
New England Journal of Medicine
, vol.329
, Issue.20
, pp. 1456-1462
-
-
Lewis, E.J.1
Hunsicker, L.G.2
Bain, R.P.3
Rohde, R.D.4
-
72
-
-
0026707841
-
Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: Does it exist and does it affect the antihypertensive response?
-
van den Meiracker AH, AJ Man in 't Veld, Admiraal PJ, et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: Does it exist and does it affect the antihypertensive response? J Hypertens. 1992;10:803-12.
-
(1992)
J Hypertens
, vol.10
, pp. 803-12
-
-
Van Den Meiracker, A.H.1
Admiraal, P.J.2
-
73
-
-
34548163060
-
The incidence and implications of aldosterone breakthrough
-
DOI 10.1038/ncpneph0575, PII NCPNEPH0575
-
Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3:486-92. (Pubitemid 47313030)
-
(2007)
Nature Clinical Practice Nephrology
, vol.3
, Issue.9
, pp. 486-492
-
-
Bomback, A.S.1
Klemmer, P.J.2
-
74
-
-
44849124747
-
Aliskiren and dual therapy in type 2 diabetes mellitus
-
DOI 10.1056/NEJMe0803375
-
Ingelfinger JR. Aliskiren and dual therapy in type 2 diabetes mellitus. N Engl J Med. 2008;358:2503-5. (Pubitemid 351793025)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.23
, pp. 2503-2505
-
-
Ingelfinger, J.R.1
-
75
-
-
0036372173
-
Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): Comparison with enalapril
-
Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): Comparison with enalapril. Hypertension. 2002;39:E1-8.
-
(2002)
Hypertension
, vol.39
-
-
Nussberger, J.1
Wuerzner, G.2
Jensen, C.3
-
76
-
-
9644287897
-
Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption
-
DOI 10.1097/01.ASN.0000146686.35541.29
-
Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15:3126-33. (Pubitemid 39578845)
-
(2004)
Journal of the American Society of Nephrology
, vol.15
, Issue.12
, pp. 3126-3133
-
-
Azizi, M.1
Menard, J.2
Bissery, A.3
Guyenne, T.-T.4
Bura-Riviere, A.5
Vaidyanathan, S.6
Camisasca, R.P.7
-
77
-
-
34548818515
-
Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals
-
Azizi M, Menard J, Bissery A, et al. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin J Am Soc Nephrol. 2007;2:947-55.
-
(2007)
Clin J Am Soc Nephrol
, vol.2
, pp. 947-55
-
-
Azizi, M.1
Menard, J.2
Bissery, A.3
-
78
-
-
34447521458
-
Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial
-
DOI 10.1016/S0140-6736(07)61124-6, PII S0140673607611246
-
Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial. Lancet. 2007;370:221-9. (Pubitemid 47069535)
-
(2007)
Lancet
, vol.370
, Issue.9583
, pp. 221-229
-
-
Oparil, S.1
Yarows, S.A.2
Patel, S.3
Fang, H.4
Zhang, J.5
Satlin, A.6
-
79
-
-
33845785350
-
Aliskiren, an Orally Effective Renin Inhibitor, Provides Antihypertensive Efficacy Alone and in Combination With Valsartan
-
DOI 10.1016/j.amjhyper.2006.06.003, PII S0895706106003669
-
Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:11-20. (Pubitemid 46014059)
-
(2007)
American Journal of Hypertension
, vol.20
, Issue.1
, pp. 11-20
-
-
Pool, J.L.1
Schmieder, R.E.2
Azizi, M.3
Aldigier, J.-C.4
Januszewicz, A.5
Zidek, W.6
Chiang, Y.7
Satlin, A.8
-
80
-
-
38649102508
-
Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension
-
DOI 10.3317/jraas.2007.028
-
Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8:190-8. (Pubitemid 351166266)
-
(2007)
JRAAS - Journal of the Renin-Angiotensin-Aldosterone System
, vol.8
, Issue.4
, pp. 190-198
-
-
Uresin, Y.1
Taylor, A.A.2
Kilo, C.3
Tschope, D.4
Santonastaso, M.5
Ibram, G.6
Fang, H.7
Satlin, A.8
-
81
-
-
44849114597
-
Aliskiren combined with losartan in type 2 diabetes and nephropathy
-
DOI 10.1056/NEJMoa0708379
-
Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-46. (Pubitemid 351793017)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.23
, pp. 2433-2446
-
-
Parving, H.-H.1
Persson, F.2
Lewis, J.B.3
Lewis, E.J.4
Hollenberg, N.K.5
-
82
-
-
57049133582
-
The effects of spironolactone on nephron function in patients with diabetic nephropathy
-
Ustundag A, Tugrul A, Ustundag S, et al. The effects of spironolactone on nephron function in patients with diabetic nephropathy. Ren Fail. 2008;30:982-91.
-
(2008)
Ren Fail
, vol.30
, pp. 982-91
-
-
Ustundag, A.1
Tugrul, A.2
Ustundag, S.3
-
83
-
-
58149125532
-
Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: Results of a randomized, placebo-controlled, double-blind, crossover trial
-
Saklayen MG, Gyebi LK, Tasosa J, et al. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: Results of a randomized, placebo-controlled, double-blind, crossover trial. J Investig Med. 2008;56:714-9.
-
(2008)
J Investig Med
, vol.56
, pp. 714-9
-
-
Saklayen, M.G.1
Gyebi, L.K.2
Tasosa, J.3
-
84
-
-
58049209809
-
Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats
-
Kang YS, Ko GJ, Lee MH, et al. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol Dial Transplant. 2009;24:73-84.
-
(2009)
Nephrol Dial Transplant
, vol.24
, pp. 73-84
-
-
Kang, Y.S.1
Ko, G.J.2
Lee, M.H.3
-
85
-
-
0001847493
-
Eplerenone 021 Investigators. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria
-
Epstein M, Buckalew VJ, Martinez F, Altamirano J, Roniker B, Kleiman J, Krause S, Eplerenone 021 Investigators. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Am J Hypertens. 2002;15:24A.
-
(2002)
Am J Hypertens
, vol.15
-
-
Epstein, M.1
Buckalew, V.J.2
Martinez, F.3
Altamirano, J.4
Roniker, B.5
Kleiman, J.6
Krause, S.7
-
86
-
-
2342559832
-
The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: A randomized controlled study
-
DOI 10.1111/j.1464-5491.2004.01194.x
-
Rachmani R, Slavachevsky I, Amit M, et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: A randomized controlled study. Diabet Med. 2004;21:471-5. (Pubitemid 38608536)
-
(2004)
Diabetic Medicine
, vol.21
, Issue.5
, pp. 471-475
-
-
Rachmani, R.1
Slavachevsky, I.2
Amit, M.3
Levi, Z.4
Kedar, Y.5
Berla, M.6
Ravid, M.7
-
87
-
-
0037222490
-
Effectiveness of aldosterone blockade in patients with diabetic nephropathy
-
DOI 10.1161/01.HYP.0000044937.95080.E9
-
Sato A, Hayashi K, Naruse M, et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64-8. (Pubitemid 36056793)
-
(2003)
Hypertension
, vol.41
, Issue.1
, pp. 64-68
-
-
Sato, A.1
Hayashi, K.2
Naruse, M.3
Saruta, T.4
-
88
-
-
24144495285
-
Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study
-
DOI 10.2337/diacare.28.9.2106
-
Rossing K, Schjoedt KJ, Smidt UM, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care. 2005;28:2106-12. (Pubitemid 41242452)
-
(2005)
Diabetes Care
, vol.28
, Issue.9
, pp. 2106-2112
-
-
Rossing, K.1
Schjoedt, K.J.2
Smidt, U.M.3
Boomsma, F.4
Parving, H.-H.5
-
89
-
-
33746566456
-
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy
-
DOI 10.1038/sj.ki.5001580, PII 5001580
-
Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006;70:536-42. (Pubitemid 44141580)
-
(2006)
Kidney International
, vol.70
, Issue.3
, pp. 536-542
-
-
Schjoedt, K.J.1
Rossing, K.2
Juhl, T.R.3
Boomsma, F.4
Tarnow, L.5
Rossing, P.6
Parving, H.-H.7
-
90
-
-
33745209933
-
Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensinconverting enzyme inhibitor
-
Ogawa S, Takeuchi K, Mori T, et al. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensinconverting enzyme inhibitor. Clin Exp Pharmacol Physiol. 2006;33:477-9.
-
(2006)
Clin Exp Pharmacol Physiol
, vol.33
, pp. 477-9
-
-
Ogawa, S.1
Takeuchi, K.2
Mori, T.3
-
91
-
-
32844467281
-
Beneficial impact of spironolactone in diabetic nephropathy
-
DOI 10.1111/j.1523-1755.2005.00756.x, PII 4495629
-
Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005;68:2829-36. (Pubitemid 43251030)
-
(2005)
Kidney International
, vol.68
, Issue.6
, pp. 2829-2836
-
-
Schjoedt, K.J.1
Rossing, K.2
Juhl, T.R.3
Boomsma, F.4
Rossing, P.5
Tarnow, L.6
Parving, H.-H.7
-
92
-
-
20544465842
-
Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study
-
DOI 10.1053/j.ajkd.2005.03.007, PII S0272638605004348
-
Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study. Am J Kidney Dis. 2005;46:45-51. (Pubitemid 40848432)
-
(2005)
American Journal of Kidney Diseases
, vol.46
, Issue.1
, pp. 45-51
-
-
Bianchi, S.1
Bigazzi, R.2
Campese, V.M.3
-
93
-
-
72049109463
-
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy
-
Mehdi UF, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20:2641-50.
-
(2009)
J Am Soc Nephrol
, vol.20
, pp. 2641-50
-
-
Mehdi, U.F.1
Adams-Huet, B.2
Raskin, P.3
-
94
-
-
0030459918
-
Renal protection in diabetes: An emerging role for calcium antagonists
-
Parving HH, Tarnow L, Rossing P. Renal protection in diabetes: An emerging role for calcium antagonists. J Hypertens Suppl. 1996;14: S21-5.
-
(1996)
J Hypertens Suppl
, vol.14
-
-
Parving, H.H.1
Tarnow, L.2
Rossing, P.3
-
95
-
-
0024205652
-
Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy
-
Mimran A, Insua A, Ribstein J, et al. Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Diabetes Care. 1988;11:850-3. (Pubitemid 19006528)
-
(1988)
Diabetes Care
, vol.11
, Issue.10
, pp. 850-853
-
-
Mimran, A.1
Insua, A.2
Ribstein, J.3
Bringer, J.4
Monnier, L.5
-
96
-
-
0024539169
-
Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive Type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: A randomised controlled trial
-
Baba T, Murabayashi S, Takebe K. Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: A randomised controlled trial. Diabetologia. 1989;32:40-4. (Pubitemid 19061740)
-
(1989)
Diabetologia
, vol.32
, Issue.1
, pp. 40-44
-
-
Baba, T.1
Murabayashi, S.2
Takebe, K.3
-
97
-
-
0025963419
-
Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria
-
Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Melbourne Diabetic Nephropathy Study Group. BMJ. 1991;302:210-216.
-
(1991)
Melbourne Diabetic Nephropathy Study Group. BMJ
, vol.302
, pp. 210-216
-
-
-
98
-
-
0001859442
-
Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes
-
Mosconi L, Ruggenenti P, Perna A, et al. Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Kidney Int Suppl. 1996;55:S91-3.
-
(1996)
Kidney Int Suppl
, vol.55
-
-
Mosconi, L.1
Ruggenenti, P.2
Perna, A.3
-
99
-
-
0028812748
-
Hypertension and non-insulindependent diabetes. A comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist
-
Crepaldi G, Carraro A, Brocco E, et al. Hypertension and non-insulindependent diabetes. A comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist. Acta Diabetol. 1995;32:203-8.
-
(1995)
Acta Diabetol
, vol.32
, pp. 203-8
-
-
Crepaldi, G.1
Carraro, A.2
Brocco, E.3
-
100
-
-
9044235779
-
Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients
-
Velussi M, Brocco E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes. 1996;45:216-22. (Pubitemid 26045805)
-
(1996)
Diabetes
, vol.45
, Issue.2
, pp. 216-222
-
-
Velussi, M.1
Brocco, E.2
Frigato, F.3
Zolli, M.4
Muollo, B.5
Maioli, M.6
Carraro, A.7
Tonolo, G.8
Fresu, P.9
Cernigoi, A.M.10
Fioretto, P.11
Nosadini, R.12
-
101
-
-
0001044921
-
Effect of amlopidine vs. fosinopril on microalbuminuria in elderly hypertensive patients with type II diabetes
-
Corradi LLP, Pasotti C, Zoppi A, Preti P, Lazzari P, et al. Effect of amlopidine vs. fosinopril on microalbuminuria in elderly hypertensive patients with type II diabetes. Am J Hypertens. 1996;9:152A.
-
(1996)
Am J Hypertens
, vol.9
-
-
Corradi, L.L.P.1
Pasotti, C.2
Zoppi, A.3
Preti, P.4
Lazzari, P.5
-
102
-
-
0343957436
-
Comparative study on renal effects of nitrendipine vs. enalapril in microalbuminuric patients with type 1 diabetes mellitus
-
Jungmann EHT, Malanyn M, Mortasawi N, Schererich J, Usadel KH. Comparative study on renal effects of nitrendipine vs. enalapril in microalbuminuric patients with type 1 diabetes mellitus. Diabetologia. 1992;35:A149.
-
(1992)
Diabetologia
, vol.35
-
-
Jungmann, E.H.T.1
Malanyn, M.2
Mortasawi, N.3
Schererich, J.4
Usadel, K.H.5
-
103
-
-
0024331937
-
Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy
-
Stornello M, Valvo EV, Scapellato L. Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy. J Cardiovasc Pharmacol. 1989;14:851-5. (Pubitemid 20008843)
-
(1989)
Journal of Cardiovascular Pharmacology
, vol.14
, Issue.6
, pp. 851-855
-
-
Stornello, M.1
Valvo, E.V.2
Scapellato, L.3
-
104
-
-
0025217243
-
Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus
-
Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med. 1990;112:707-8. (Pubitemid 20137180)
-
(1990)
Annals of Internal Medicine
, vol.112
, Issue.9
, pp. 707-708
-
-
Bakris, G.L.1
-
105
-
-
0026806608
-
Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients
-
Romero R, Salinas I, Lucas A, et al. Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients. Diabetes Res Clin Pract. 1992;17:191-8.
-
(1992)
Diabetes Res Clin Pract
, vol.17
, pp. 191-8
-
-
Romero, R.1
Salinas, I.2
Lucas, A.3
-
106
-
-
0026600686
-
Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients
-
Ferder L, Daccordi H, Martello M, et al. Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension. 1992;19:II237-42.
-
(1992)
Hypertension
, vol.19
, pp. 237-242
-
-
Ferder, L.1
Daccordi, H.2
Martello, M.3
-
107
-
-
0026534833
-
Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection
-
Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection. Kidney Int. 1992;41:912-9.
-
(1992)
Kidney Int
, vol.41
, pp. 912-9
-
-
Bakris, G.L.1
Barnhill, B.W.2
Sadler, R.3
-
108
-
-
0027772076
-
A comparison of spirapril and isradipine in patients with diabetic nephropathy and hypertension
-
Norgaard K, Jensen T, Christensen P, et al. A comparison of spirapril and isradipine in patients with diabetic nephropathy and hypertension. Blood Press. 1993;2:301-8. (Pubitemid 24026309)
-
(1993)
Blood Pressure
, vol.2
, Issue.4
, pp. 301-308
-
-
Norgaard, K.1
Jensen, T.2
Christensen, P.3
Feldt-Rasmussen, B.4
-
109
-
-
0031051404
-
Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment
-
Rossing P, Tarnow L, Boelskifte S, et al. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes. 1997;46:481-7. (Pubitemid 27090279)
-
(1997)
Diabetes
, vol.46
, Issue.3
, pp. 481-487
-
-
Rossing, P.1
Tarnow, L.2
Boelskifte, S.3
Jensen, B.R.4
Nielsen, F.S.5
Parving, H.-H.6
-
110
-
-
24844476907
-
Long term effects of ramipril and nitrendipine on albuminuria in diabetic hypertensive patients with impaired renal function
-
Corradi LFR, Zoppi A, Lusardi P, Preti P, Lazzari P, et al. Long term effects of ramipril and nitrendipine on albuminuria in diabetic hypertensive patients with impaired renal function. Am J Hypertens. 1996;9:151A.
-
(1996)
Am J Hypertens
, vol.9
-
-
Corradi, L.F.R.1
Zoppi, A.2
Lusardi, P.3
Preti, P.4
Lazzari, P.5
-
111
-
-
0000645687
-
Effect of nondihydropyridine calcium antagonists (NDCAs) on progression of nephropathy from noninsulin dependent diabetes (NIDDM
-
Bakris GL CJ, Vicknair N, Leurgans S. Effect of nondihydropyridine calcium antagonists (NDCAs) on progression of nephropathy from noninsulin dependent diabetes (NIDDM). J Am Soc Nephrol. 1995;6:446.
-
(1995)
J Am Soc Nephrol
, vol.6
, pp. 446
-
-
Bakris, G.L.C.J.1
Vicknair, N.2
Leurgans, S.3
-
112
-
-
24844463607
-
Comparative study of lisinopril and nifedipine in treatment of diabetic patients with hypertension and macroproteinuria
-
O'Donnell MJ, Rowe B, Lawson N, Horton A, Gide OHV, Barnett AH. Comparative study of lisinopril and nifedipine in treatment of diabetic patients with hypertension and macroproteinuria. Diabetes. 1991;40:505A.
-
(1991)
Diabetes
, vol.40
-
-
O'Donnell, M.J.1
Rowe, B.2
Lawson, N.3
Horton, A.4
Gide, O.H.V.5
Barnett, A.H.6
-
113
-
-
1842330085
-
Lisinopril but not nifedipine reduces urinary albumin excretion in diabetic nephropathy
-
Holdaas H, Hartmann A, Lien MG, Nielsen L, Fauchald T, Jervell J, et al. Lisinopril but not nifedipine reduces urinary albumin excretion in diabetic nephropathy. Kidney Int. 1990;37:239.
-
(1990)
Kidney Int
, vol.37
, pp. 239
-
-
Holdaas, H.1
Hartmann, A.2
Lien, M.G.3
Nielsen, L.4
Fauchald, T.5
Jervell, J.6
-
114
-
-
57349138291
-
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
-
Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-28.
-
(2008)
N Engl J Med
, vol.359
, pp. 2417-28
-
-
Jamerson, K.1
Weber, M.A.2
Bakris, G.L.3
-
115
-
-
77950187294
-
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecified secondary analysis of a randomised controlled trial
-
Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375:1173-81.
-
(2010)
Lancet
, vol.375
, pp. 1173-81
-
-
Bakris, G.L.1
Sarafidis, P.A.2
Weir, M.R.3
-
116
-
-
2442703942
-
Differential effects of calcium antagonist subclasses on markers of nephropathy progression
-
DOI 10.1111/j.1523-1755.2004.00620.x
-
Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004;65:1991-2002. (Pubitemid 38669986)
-
(2004)
Kidney International
, vol.65
, Issue.6
, pp. 1991-2002
-
-
Bakris, G.L.1
Weir, M.R.2
Secic, M.3
Campbell, B.4
Weis-McNulty, A.5
-
117
-
-
0031042356
-
Understanding the nature of renal disease progression
-
Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int. 1997;51:2-15. (Pubitemid 27064516)
-
(1997)
Kidney International
, vol.51
, Issue.1
, pp. 2-15
-
-
Remuzzi, G.1
Ruggenenti, P.2
Benigni, A.3
-
119
-
-
0028887054
-
Antiproteinuric effect of blood-pressure-lowering agents: A meta-analysis of comparative trials
-
Gansevoort RT, Sluiter WJ, Hemmelder MH, et al. Antiproteinuric effect of blood-pressure-lowering agents: A meta-analysis of comparative trials. Nephrol Dial Transplant. 1995;10:1963-74.
-
(1995)
Nephrol Dial Transplant
, vol.10
, pp. 1963-74
-
-
Gansevoort, R.T.1
Sluiter, W.J.2
Hemmelder, M.H.3
-
120
-
-
0029961207
-
Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy
-
Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996;50:1641-50. (Pubitemid 26364270)
-
(1996)
Kidney International
, vol.50
, Issue.5
, pp. 1641-1650
-
-
Bakris, G.L.1
Copley, J.B.2
Vicknair, N.3
Sadler, R.4
Leurgans, S.5
-
121
-
-
0031020448
-
Effect of calcium channel or β-blockade on the progression of diabetic nephropathy in African Americans
-
Bakris GL, Mangrum A, Copley JB, et al. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension. 1997;29:744-50. (Pubitemid 27097979)
-
(1997)
Hypertension
, vol.29
, Issue.3
, pp. 744-750
-
-
Bakris, G.L.1
Mangrum, A.2
Copley, J.B.3
Vicknair, N.4
Sadler, R.5
-
122
-
-
0037431774
-
Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial
-
DOI 10.1016/S0140-6736(03)12229-5
-
Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet. 2003;361:117-24. (Pubitemid 36092015)
-
(2003)
Lancet
, vol.361
, Issue.9352
, pp. 117-124
-
-
Nakao, N.1
Yoshimura, A.2
Morita, H.3
Takada, M.4
Kayano, T.5
Ideura, T.6
-
123
-
-
0032911972
-
Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation
-
Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation. Am J Kidney Dis. 1999;33:1004-10. (Pubitemid 29214705)
-
(1999)
American Journal of Kidney Diseases
, vol.33
, Issue.5
, pp. 1004-1010
-
-
Keane, W.F.1
Eknoyan, G.2
Willis, K.3
-
124
-
-
0030980370
-
Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy
-
Nielsen FS, Rossing P, Gall MA, et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes. 1997;46:1182-8. (Pubitemid 27271080)
-
(1997)
Diabetes
, vol.46
, Issue.7
, pp. 1182-1188
-
-
Nielsen, F.S.1
Rossing, P.2
Gall, M.-A.3
Skott, P.4
Smidt, U.M.5
Parving, H.-H.6
-
125
-
-
0032511601
-
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
-
UK Prospective Diabetes Study Group
-
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998;317:713-720.
-
(1998)
BMJ
, vol.317
, pp. 713-720
-
-
-
126
-
-
3843080677
-
Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The NESTOR study
-
DOI 10.1097/01.hjh.0000133733.32125.09
-
Marre M, Puig JG, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The NESTOR Study. J Hypertens. 2004;22:1613-22. (Pubitemid 39037614)
-
(2004)
Journal of Hypertension
, vol.22
, Issue.8
, pp. 1613-1622
-
-
Marre, M.1
Puig, J.G.2
Kokot, F.3
Fernandez, M.4
Jermendy, G.5
Opie, L.6
Moyseev, V.7
Scheen, A.8
Ionescu-Tirgoviste, C.9
Helena Saldanha, M.10
Halabe, A.11
Williams, B.12
Decio Jr., M.13
Ruiz, M.14
Hermansen, K.15
Tuomilehto, J.16
Finizola, B.17
Gallois, Y.18
Amouyel, P.19
Ollivier, J.-P.20
Asmar, R.21
more..
-
127
-
-
43749112197
-
Effects of different ACE inhibitor combinations on albuminuria: Results of the GUARD study
-
DOI 10.1038/ki.2008.102, PII KI2008102
-
Bakris GL, Toto RD, McCullough PA, et al. Effects of different ACE inhibitor combinations on albuminuria: Results of the GUARD study. Kidney Int. 2008;73:1303-9. (Pubitemid 351693145)
-
(2008)
Kidney International
, vol.73
, Issue.11
, pp. 1303-1309
-
-
Bakris, G.L.1
Toto, R.D.2
McCullough, P.A.3
Rocha, R.4
Purkayastha, D.5
Davis, P.6
-
128
-
-
83055172414
-
K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease
-
National Kidney Foundation
-
National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003;41:S1-92.
-
(2003)
Am J Kidney Dis
, vol.41
-
-
-
130
-
-
32544443164
-
Review: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia
-
DOI 10.1210/jc.2005-2084
-
Ginsberg HN. REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab. 2006;91:383-92. (Pubitemid 43236897)
-
(2006)
Journal of Clinical Endocrinology and Metabolism
, vol.91
, Issue.2
, pp. 383-392
-
-
Ginsberg, H.N.1
-
131
-
-
0026710526
-
Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study
-
Koskinen P, Manttari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992;15:820-5.
-
(1992)
Diabetes Care
, vol.15
, pp. 820-5
-
-
Koskinen, P.1
Manttari, M.2
Manninen, V.3
-
132
-
-
0032572086
-
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
-
DOI 10.1001/jama.279.20.1615
-
Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22. (Pubitemid 28248586)
-
(1998)
Journal of the American Medical Association
, vol.279
, Issue.20
, pp. 1615-1622
-
-
Downs, J.R.1
Clearfield, M.2
Weis, S.3
Whitney, E.4
Shapiro, D.R.5
Beere, P.A.6
Langendorfer, A.7
Stein, E.A.8
Kruyer, W.9
Gotto Jr., A.M.10
-
133
-
-
0037132607
-
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHATLLT
-
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHATLLT). JAMA. 2002;288:2998-3007.
-
(2002)
JAMA
, vol.288
, pp. 2998-3007
-
-
-
134
-
-
0037031061
-
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial
-
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360:7-22.
-
(2002)
Lancet
, vol.360
, pp. 7-22
-
-
-
135
-
-
0037840242
-
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-control led trial
-
Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-control led trial . Lancet. 2003;361:2005-16.
-
(2003)
Lancet
, vol.361
, pp. 2005-16
-
-
Collins, R.1
Armitage, J.2
Parish, S.3
-
136
-
-
0037164314
-
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial
-
DOI 10.1016/S0140-6736(02)11600-X
-
Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet. 2002;360:1623-30. (Pubitemid 35379733)
-
(2002)
Lancet
, vol.360
, Issue.9346
, pp. 1623-1630
-
-
Shepherd, J.1
Blauw, G.J.2
Murphy, M.B.3
Bollen, E.L.E.M.4
Buckley, B.M.5
Cobbe, S.M.6
Ford, I.7
Gaw, A.8
Hyland, M.9
Jukema, J.W.10
Kamper, A.M.11
Macfarlane, P.W.12
Meinders, A.E.13
Norrie, J.14
Packard, C.J.15
Perry, I.J.16
Stott, D.J.17
Sweeney, B.J.18
Twomey, C.19
Westendorp, R.G.J.20
more..
-
137
-
-
20944448451
-
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA)
-
DOI 10.2337/diacare.28.5.1151
-
Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005;28:1151-7. (Pubitemid 40616627)
-
(2005)
Diabetes Care
, vol.28
, Issue.5
, pp. 1151-1157
-
-
Sever, P.S.1
Poulter, N.R.2
Dahlof, B.3
Wedel, H.4
Collins, R.5
Beevers, G.6
Caulfield, M.7
Kjeldsen, S.E.8
Kristinsson, A.9
McInnes, G.T.10
Mehlsen, J.11
Nieminen, M.12
O'Brien, E.13
Ostergren, J.14
-
138
-
-
4444382862
-
Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus background paper for the American College of Physicians
-
Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: Background paper for the American College of Physicians. Ann Intern Med. 2004;140:650-8.
-
(2004)
Ann Intern Med
, vol.140
, pp. 650-8
-
-
Vijan, S.1
Hayward, R.A.2
-
139
-
-
0037458229
-
Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency
-
Tonelli M, Moye L, Sacks FM, et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med. 2003;138:98-104. (Pubitemid 36222496)
-
(2003)
Annals of Internal Medicine
, vol.138
, Issue.2
, pp. 98-104
-
-
Tonelli, M.1
Moye, L.2
Sacks, F.M.3
Kiberd, B.4
Curhan, G.5
-
140
-
-
38949210220
-
Effect of a multifactorial intervention on mortality in type 2 diabetes
-
DOI 10.1056/NEJMoa0706245
-
Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-91. (Pubitemid 351214285)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.6
, pp. 580-591
-
-
Gaede, P.1
Lund-Andersen, H.2
Parving, H.-H.3
Pedersen, O.4
-
141
-
-
33748161712
-
Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease
-
DOI 10.1093/ndt/gfl198
-
Jones C, Roderick P, Harris S, et al. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transplant. 2006;21:2133-43. (Pubitemid 44313384)
-
(2006)
Nephrology Dialysis Transplantation
, vol.21
, Issue.8
, pp. 2133-2143
-
-
Jones, C.1
Roderick, P.2
Harris, S.3
Rogerson, M.4
-
142
-
-
36448979949
-
Outcomes in patients with chronic kidney disease referred late to nephrologists: A meta-analysis
-
Chan MR, Dall AT, Fletcher KE, et al. Outcomes in patients with chronic kidney disease referred late to nephrologists: A meta-analysis. Am J Med. 2007;120:1063-70.
-
(2007)
Am J Med
, vol.120
, pp. 1063-70
-
-
Chan, M.R.1
Dall, A.T.2
Fletcher, K.E.3
-
143
-
-
0037163490
-
Nephrologist care and mortality in patients with chronic renal insufficiency
-
Avorn J, Bohn RL, Levy E, et al. Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Intern Med. 2002;162:2002-6.
-
(2002)
Arch Intern Med
, vol.162
, pp. 2002-6
-
-
Avorn, J.1
Bohn, R.L.2
Levy, E.3
-
144
-
-
0037125881
-
The timing of specialist evaluation in chronic kidney disease and mortality
-
Kinchen KS, Sadler J, Fink N, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med. 2002;137:479-86. (Pubitemid 35024618)
-
(2002)
Annals of Internal Medicine
, vol.137
, Issue.6
, pp. 479-486
-
-
Kinchen, K.S.1
Sadler, J.2
Fink, N.3
Brookmeyer, R.4
Klag, M.J.5
Levey, A.S.6
Powe, N.R.7
-
145
-
-
0036849925
-
The role of comprehensive renal clinic in chronic kidney disease stabilization and management: The Northwestern experience
-
Ghossein C, Serrano A, Rammohan M, et al. The role of comprehensive renal clinic in chronic kidney disease stabilization and management: The Northwestern experience. Semin Nephrol. 2002;22:526-32. (Pubitemid 35351264)
-
(2002)
Seminars in Nephrology
, vol.22
, Issue.6
, pp. 526-532
-
-
Ghossein, C.1
Serrano, A.2
Rammohan, M.3
Batlle, D.4
-
146
-
-
0035786908
-
Insulin resistance and its treatment by thiazolidinediones
-
Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res. 2001;56:265-94.
-
(2001)
Recent Prog Horm Res
, vol.56
, pp. 265-94
-
-
Lebovitz, H.E.1
Banerji, M.A.2
-
147
-
-
2542424151
-
Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes
-
DOI 10.2337/diacare.27.6.1349
-
Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care. 2004;27:1349-57. (Pubitemid 38679982)
-
(2004)
Diabetes Care
, vol.27
, Issue.6
, pp. 1349-1357
-
-
Natali, A.1
Baldeweg, S.2
Toschi, E.3
Capaldo, B.4
Barbaro, D.5
Gastaldelli, A.6
Yudkin, J.S.7
Ferrannini, E.8
-
148
-
-
0842289940
-
In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control
-
DOI 10.2337/diacare.27.2.484
-
Pistrosch F, Passauer J, Fischer S, et al. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care. 2004;27:484-90. (Pubitemid 38174076)
-
(2004)
Diabetes Care
, vol.27
, Issue.2
, pp. 484-490
-
-
Pistrosch, F.1
Passauer, J.2
Fischer, S.3
Fuecker, K.4
Hanefeld, M.5
Gross, P.6
-
149
-
-
0031888958
-
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
-
DOI 10.1038/34184
-
Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-6. (Pubitemid 28079219)
-
(1998)
Nature
, vol.391
, Issue.6662
, pp. 82-86
-
-
Jiang, C.1
Ting, A.T.2
Seed, B.3
-
150
-
-
17644423543
-
Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone
-
DOI 10.1161/01.CIR.0000161954.17870.5D
-
Harte A, McTernan P, Chetty R, et al. Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation. 2005;111:1954-61. (Pubitemid 40570215)
-
(2005)
Circulation
, vol.111
, Issue.15
, pp. 1954-1961
-
-
Harte, A.1
McTernan, P.2
Chetty, R.3
Coppack, S.4
Katz, J.5
Smith, S.6
Kumar, S.7
-
151
-
-
0034633847
-
Peroxisome proliferatoractivated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells
-
Takeda K, Ichiki T, Tokunou T, et al. Peroxisome proliferatoractivated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation. 2000;102:1834-9.
-
(2000)
Circulation
, vol.102
, pp. 1834-9
-
-
Takeda, K.1
Ichiki, T.2
Tokunou, T.3
-
152
-
-
0034968295
-
Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes
-
DOI 10.1291/hypres.24.229
-
Sugawara A, Takeuchi K, Uruno A, et al. Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes. Hypertens Res. 2001;24:229-33. (Pubitemid 32577144)
-
(2001)
Hypertension Research
, vol.24
, Issue.3
, pp. 229-233
-
-
Sugawara, A.1
Takeuchi, K.2
Uruno, A.3
Ikeda, Y.4
Arima, S.5
Sato, K.6
Kudo, M.7
Taniyama, Y.8
Ito, S.9
-
153
-
-
0033669212
-
Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients
-
Nakamura T, Ushiyama C, Shimada N, et al. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications. 2000;14:250-4.
-
(2000)
J Diabetes Complications
, vol.14
, pp. 250-4
-
-
Nakamura, T.1
Ushiyama, C.2
Shimada, N.3
-
154
-
-
0037369871
-
PPAR agonists protect mesangial cells from interleukin 1β-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway
-
DOI 10.1097/01.ASN.0000050414.52908.DA
-
Ruan XZ, Moorhead JF, Fernando R, et al. PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J Am Soc Nephrol. 2003;14:593-600. (Pubitemid 36246002)
-
(2003)
Journal of the American Society of Nephrology
, vol.14
, Issue.3
, pp. 593-600
-
-
Ruan, X.Z.1
Moorhead, J.F.2
Fernando, R.3
Wheeler, D.C.4
Powis, S.H.5
Varghese, Z.6
-
155
-
-
6344292325
-
Liver X receptor-α mediates cholesterol efflux in glomerular mesangial cells
-
DOI 10.1152/ajprenal.00123.2004
-
Wu J, Zhang Y, Wang N, et al. Liver X receptor-alpha mediates cholesterol efflux in glomerular mesangial cells. Am J Physiol Renal Physiol. 2004;287:F886-95. (Pubitemid 39391085)
-
(2004)
American Journal of Physiology - Renal Physiology
, vol.287
, Issue.5
-
-
Wu, J.1
Zhang, Y.2
Wang, N.3
Davis, L.4
Yang, G.5
Wang, X.6
Zhu, Y.7
Breyer, M.D.8
Guan, Y.9
-
156
-
-
2442678866
-
Differential effects of peroxisome proliferator activated receptor-γ (PPARγ) ligands in proximal tubular cells: Thiazolidinediones are partial PPARγ agonists
-
DOI 10.1111/j.1523-1755.2004.00624.x
-
Chana RS, Lewington AJ, Brunskill NJ. Differential effects of peroxisome proliferator activated receptor-gamma (PPAR gamma) ligands in proximal tubular cells: Thiazolidinediones are partial PPAR gamma agonists. Kidney Int. 2004;65:2081-90. (Pubitemid 38669994)
-
(2004)
Kidney International
, vol.65
, Issue.6
, pp. 2081-2090
-
-
Chana, R.S.1
Lewington, A.J.2
Brunskill, N.J.3
-
157
-
-
4143099046
-
The effect of high glucose and PPAR-γ agonists on PPAR-γ expression and function in HK-2 cells
-
DOI 10.1152/ajprenal.00445.2003
-
Panchapakesan U, Pollock CA, Chen XM. The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells. Am J Physiol Renal Physiol. 2004;287:F528-34. (Pubitemid 39095968)
-
(2004)
American Journal of Physiology - Renal Physiology
, vol.287
, Issue.3
-
-
Panchapakesan, U.1
Pollock, C.A.2
Chen, X.M.3
-
158
-
-
0030825304
-
Antihypertensive and vasculo-and renoprotective effects of pioglitazone in genetically obese diabetic rats
-
Yoshimoto T, Naruse M, Nishikawa M, et al. Antihypertensive and vasculo-and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol. 1997;272:E989-96.
-
(1997)
Am J Physiol
, vol.272
-
-
Yoshimoto, T.1
Naruse, M.2
Nishikawa, M.3
-
159
-
-
0031847401
-
Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in zucker fatty rats
-
DOI 10.2337/diabetes.47.8.1326
-
Buckingham RE, Al-Barazanji KA, Toseland CD, et al. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes. 1998;47:1326-34. (Pubitemid 28357012)
-
(1998)
Diabetes
, vol.47
, Issue.8
, pp. 1326-1334
-
-
Buckingham, R.E.1
Al-Barazanji, K.A.2
Toseland, C.D.N.3
Slaughter, M.4
Connor, S.C.5
West, A.6
Bond, B.7
Turner, N.C.8
Clapham, J.C.9
-
160
-
-
0036116895
-
Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat
-
DOI 10.1053/meta.2002.30953
-
Yamashita H, Nagai Y, Takamura T, et al. Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. Metabolism. 2002;51:403-8. (Pubitemid 34406552)
-
(2002)
Metabolism: Clinical and Experimental
, vol.51
, Issue.4
, pp. 403-408
-
-
Yamashita, H.1
Nagai, Y.2
Takamura, T.3
Nohara, E.4
Kobayashi, K.-I.5
-
161
-
-
0034033786
-
Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats
-
Isshiki K, Haneda M, Koya D, et al. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes. 2000;49:1022-32. (Pubitemid 30349426)
-
(2000)
Diabetes
, vol.49
, Issue.6
, pp. 1022-1032
-
-
Isshiki, K.1
Haneda, M.2
Koya, D.3
Maeda, S.4
Sugimoto, T.5
Kikkawa, R.6
-
162
-
-
0345599866
-
Peroxisome Proliferator-Activated Receptor γ Agonist Provides Superior Renal Protection versus Angiotensin-Converting Enzyme Inhibition in a Rat Model of Type 2 Diabetes with Obesity
-
DOI 10.1124/jpet.103.055616
-
Baylis C, Atzpodien EA, Freshour G, et al. Peroxisome proliferatoractivated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther. 2003;307:854-60. (Pubitemid 37494201)
-
(2003)
Journal of Pharmacology and Experimental Therapeutics
, vol.307
, Issue.3
, pp. 854-860
-
-
Baylis, C.1
Atzpodien, E.-A.2
Freshour, G.3
Engels, K.4
-
163
-
-
0035126947
-
Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure
-
DOI 10.1097/00004872-200103000-00019
-
Yoshida K, Kohzuki M, Xu HL, et al. Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure. J Hypertens. 2001;19:503-10. (Pubitemid 32195387)
-
(2001)
Journal of Hypertension
, vol.19
, Issue.3
, pp. 503-510
-
-
Yoshida, K.1
Kohzuki, M.2
Xu, H.-L.3
Wu, X.-M.4
Kamimoto, M.5
Sato, T.6
-
164
-
-
0031768586
-
Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy
-
Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care. 1998;21:2135-9. (Pubitemid 28549163)
-
(1998)
Diabetes Care
, vol.21
, Issue.12
, pp. 2135-2139
-
-
Imano, E.1
Kanda, T.2
Nakatani, Y.3
Nishida, T.4
Arai, K.5
Motomura, M.6
Kajimoto, Y.7
Yamasaki, Y.8
Hori, M.9
-
165
-
-
0034949794
-
Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria
-
DOI 10.1046/j.1464-5491.2001.00463.x
-
Nakamura T, Ushiyama C, Suzuki S, et al. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med. 2001;18:308-13. (Pubitemid 32579361)
-
(2001)
Diabetic Medicine
, vol.18
, Issue.4
, pp. 308-313
-
-
Nakamura, T.1
Ushiyama, C.2
Suzuki, S.3
Shimada, N.4
Sekizuka, K.5
Ebihara, L.6
Koide, H.7
-
166
-
-
0034758754
-
Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria
-
DOI 10.1053/meta.2001.26703
-
Nakamura T, Ushiyama C, Osada S, et al. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism. 2001;50:1193-6. (Pubitemid 33034703)
-
(2001)
Metabolism: Clinical and Experimental
, vol.50
, Issue.10
, pp. 1193-1196
-
-
Nakamura, T.1
Ushiyama, C.2
Osada, S.3
Hara, M.4
Shimada, N.5
Koide, H.6
-
167
-
-
1242283924
-
Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: A prospective, randomized trial
-
DOI 10.1016/j.amjmed.2003.07.023
-
Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: A prospective, randomized trial. Am J Med. 2004;116:230-5. (Pubitemid 38224230)
-
(2004)
American Journal of Medicine
, vol.116
, Issue.4
, pp. 230-235
-
-
Aljabri, K.1
Kozak, S.E.2
Thompson, D.M.3
-
168
-
-
1842506316
-
Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes
-
DOI 10.1016/j.metabol.2003.10.025
-
Yanagawa T, Araki A, Sasamoto K, et al. Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes. Metabolism. 2004;53:353-7. (Pubitemid 38684697)
-
(2004)
Metabolism: Clinical and Experimental
, vol.53
, Issue.3
, pp. 353-357
-
-
Yanagawa, T.1
Araki, A.2
Sasamoto, K.3
Shirabe, S.4
Yamanouchi, T.5
-
169
-
-
1042268736
-
One-year glycemic control with a suifonyurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes
-
DOI 10.2337/diacare.27.1.141
-
Hanefeld M, Brunetti P, Schernthaner GH, et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004;27:141-7. (Pubitemid 38196723)
-
(2004)
Diabetes Care
, vol.27
, Issue.1
, pp. 141-147
-
-
Hanefeld, M.1
Brunetti, P.2
Schernthaner, G.H.3
Matthews, D.R.4
Charbonnel, B.H.5
-
170
-
-
10344240901
-
Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: A double-blind, randomized trial
-
DOI 10.1210/jc.2003-030861
-
Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: A double-blind, randomized trial. J Clin Endocrinol Metab. 2004;89:6068-76. (Pubitemid 39628416)
-
(2004)
Journal of Clinical Endocrinology and Metabolism
, vol.89
, Issue.12
, pp. 6068-6076
-
-
Schernthaner, G.1
Matthews, D.R.2
Charbonnel, B.3
Hanefeld, M.4
Brunetti, P.5
-
171
-
-
24944536256
-
A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy
-
DOI 10.1111/j.1523-1755.2005.00416.x, PII 4494587
-
Agarwal R, Saha C, Battiwala M, et al. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int. 2005;68:285-92. (Pubitemid 43181387)
-
(2005)
Kidney International
, vol.68
, Issue.1
, pp. 285-292
-
-
Agarwal, R.1
Saha, C.2
Battiwala, M.3
Vasavada, N.4
Curley, T.5
Chase, S.D.6
Sachs, N.7
Semret, M.H.8
-
172
-
-
0035140430
-
Rosiglitazone monotherapy is effective in patients with type 2 diabetes
-
DOI 10.1210/jc.86.1.280
-
Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86:280-8. (Pubitemid 32109807)
-
(2001)
Journal of Clinical Endocrinology and Metabolism
, vol.86
, Issue.1
, pp. 280-288
-
-
Lebovitz, H.E.1
Dole, J.F.2
Patwardhan, R.3
Rappaport, E.B.4
Freed, M.I.5
-
173
-
-
14744285718
-
The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension
-
DOI 10.1016/j.amjhyper.2004.09.010
-
Sarafidis PA, Lasaridis AN, Nilsson PM, et al. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Am J Hypertens. 2005;18:227-34. (Pubitemid 40332553)
-
(2005)
American Journal of Hypertension
, vol.18
, Issue.2
, pp. 227-234
-
-
Sarafidis, P.A.1
Lasaridis, A.N.2
Nilsson, P.M.3
Hitoglou-Makedou, A.D.4
Pagkalos, E.M.5
Yovos, J.G.6
Pliakos, C.I.7
Tourkantonis, A.A.8
-
174
-
-
21344466513
-
Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients
-
DOI 10.2337/diabetes.54.7.2206
-
Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes. 2005;54:2206-11. (Pubitemid 40911285)
-
(2005)
Diabetes
, vol.54
, Issue.7
, pp. 2206-2211
-
-
Pistrosch, F.1
Herbrig, K.2
Kindel, B.3
Passauer, J.4
Fischer, S.5
Gross, P.6
-
175
-
-
33748556888
-
Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria
-
DOI 10.1097/01.hjh.0000244955.39491.88, PII 0000487220061000000022
-
Bakris GL, Ruilope LM, McMorn SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006;24:2047-55. (Pubitemid 44371272)
-
(2006)
Journal of Hypertension
, vol.24
, Issue.10
, pp. 2047-2055
-
-
Bakris, G.L.1
Ruilope, L.M.2
McMorn, S.O.3
Weston, W.M.4
Heise, M.A.5
Freed, M.I.6
Porter, L.E.7
-
176
-
-
77954988618
-
Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone
-
Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304:411-8.
-
(2010)
JAMA
, vol.304
, pp. 411-8
-
-
Graham, D.J.1
Ouellet-Hellstrom, R.2
MaCurdy, T.E.3
-
177
-
-
33846989363
-
The emerging role of angiotensin-converting enzyme-2 in the kidney
-
Burns KD. The emerging role of angiotensin-converting enzyme-2 in the kidney. Curr Opin Nephrol Hypertens. 2007;16:116-21.
-
(2007)
Curr Opin Nephrol Hypertens
, vol.16
, pp. 116-21
-
-
Burns, K.D.1
-
178
-
-
6344246036
-
Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism
-
DOI 10.1042/BJ20040634
-
Rice GI, Thomas DA, Grant PJ, et al. Evaluation of angiotensinconverting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004;383:45-51. (Pubitemid 39389449)
-
(2004)
Biochemical Journal
, vol.383
, Issue.1
, pp. 45-51
-
-
Rice, G.I.1
Thomas, D.A.2
Grant, P.J.3
Turner, A.J.4
Hooper, N.M.5
-
179
-
-
0036194890
-
Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles
-
DOI 10.1161/hy0302.104673
-
Ren Y, Garvin JL, Carretero OA. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension. 2002;39:799-802. (Pubitemid 34252879)
-
(2002)
Hypertension
, vol.39
, Issue.3
, pp. 799-802
-
-
Ren, Y.1
Garvin, J.L.2
Carretero, O.A.3
-
180
-
-
33750722109
-
Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: Implications for albuminuria in diabetes
-
DOI 10.1681/ASN.2006050423
-
Ye M, Wysocki J, William J, et al. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: Implications for albuminuria in diabetes. J Am Soc Nephrol. 2006;17:3067-75. (Pubitemid 44707767)
-
(2006)
Journal of the American Society of Nephrology
, vol.17
, Issue.11
, pp. 3067-3075
-
-
Ye, M.1
Wysocki, J.2
William, J.3
Soler, M.J.4
Cokic, I.5
Batlle, D.6
-
181
-
-
0023859136
-
A novel potent vasoconstrictor peptide produced by vascular endothelial cells
-
DOI 10.1038/332411a0
-
Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-5. (Pubitemid 18090241)
-
(1988)
Nature
, vol.332
, Issue.6163
, pp. 411-415
-
-
Yanagisawa, M.1
Kurihara, H.2
Kimura, S.3
Tomobe, Y.4
Kobayashi, M.5
Mitsui, Y.6
Goto, K.7
Masaki, T.8
Yazaki, Y.9
-
182
-
-
0041703027
-
Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation
-
Minchenko AG, Stevens MJ, White L, et al. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J. 2003;17:1514-6.
-
(2003)
FASEB J
, vol.17
, pp. 1514-6
-
-
Minchenko, A.G.1
Stevens, M.J.2
White, L.3
-
183
-
-
0031630241
-
Renal endothelin system in diabetes: Comparison of angiotensin-converting enzyme inhibition and endothelin-A antagonism
-
Hocher B, Lun A, Priem F, et al. Renal endothelin system in diabetes: Comparison of angiotensin-converting enzyme inhibition and endothelin-A antagonism. J Cardiovasc Pharmacol. 1998;31(Suppl 1):S492-5. (Pubitemid 128709991)
-
(1998)
Journal of Cardiovascular Pharmacology
, vol.31
, Issue.SUPPL. 1
-
-
Hocher, B.1
Lun, A.2
Priem, F.3
Neumayer, H.-H.4
Raschack, M.5
-
185
-
-
0029010570
-
Defining the role of endothelins in renal pathophysiology on the basis of selective and unselective endothelin receptor antagonist studies
-
Benigni A. Defining the role of endothelins in renal pathophysiology on the basis of selective and unselective endothelin receptor antagonist studies. Curr Opin Nephrol Hypertens. 1995;4:349-53.
-
(1995)
Curr Opin Nephrol Hypertens
, vol.4
, pp. 349-53
-
-
Benigni, A.1
-
186
-
-
0027739276
-
Autocrine role of endothelin in rat inner medullary collecting duct: Inhibition of AVP-induced cAMP accumulation
-
Kohan DE. Autocrine role of endothelin in rat inner medullary collecting duct: Inhibition of AVP-induced cAMP accumulation. J Cardiovasc Pharmacol. 1993;22(Suppl 8):S174-9.
-
(1993)
J Cardiovasc Pharmacol
, vol.22
, Issue.SUPPL. 8
-
-
Kohan, D.E.1
-
187
-
-
4344622740
-
Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention
-
DOI 10.1172/JCI200421064
-
Ahn D, Ge Y, Stricklett PK, et al. Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest. 2004;114:504-11. (Pubitemid 39572100)
-
(2004)
Journal of Clinical Investigation
, vol.114
, Issue.4
, pp. 504-511
-
-
Ahn, D.1
Ge, Y.2
Stricklett, P.K.3
Gill, P.4
Taylor, D.5
Hughes, A.K.6
Yanagisawa, M.7
Miller, L.8
Nelson, R.D.9
Kohan, D.E.10
-
188
-
-
0028344196
-
Increased urinary endothelin-1-like immunoreactivity excretion in NIDDM patients with albuminuria
-
Lee YJ, Shin SJ, Tsai JH. Increased urinary endothelin-1-like immunoreactivity excretion in NIDDM patients with albuminuria. Diabetes Care. 1994;17:263-6.
-
(1994)
Diabetes Care
, vol.17
, pp. 263-6
-
-
Lee, Y.J.1
Shin, S.J.2
Tsai, J.H.3
-
189
-
-
0031847324
-
Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy
-
DOI 10.1016/S0895-7061(98)00094-6, PII S0895706198000946
-
De Mattia G, Cassone-Faldetta M, Bellini C, et al. Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy. Am J Hypertens. 1998;11:983-8. (Pubitemid 28378413)
-
(1998)
American Journal of Hypertension
, vol.11
, Issue.8
, pp. 983-988
-
-
De Mattia, G.1
Cassone-Faldetta, M.2
Bellini, C.3
Bravi, M.C.4
Laurenti, O.5
Baldoncini, R.6
Santucci, A.7
Ferri, C.8
-
190
-
-
0035015691
-
The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2 diabetes mellitus
-
DOI 10.1016/S1056-8727(01)00137-4, PII S1056872701001374
-
Ak G, Buyukberber S, Sevinc A, et al. The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2 diabetes mellitus. J Diabetes Complications. 2001;15:150-7. (Pubitemid 32453172)
-
(2001)
Journal of Diabetes and its Complications
, vol.15
, Issue.3
, pp. 150-157
-
-
Ak, G.1
Buyukberber, S.2
Sevinc, A.3
Turk, H.M.4
Ates, M.5
Sari, R.6
Savli, H.7
Cigli, A.8
-
191
-
-
0036657216
-
Haemodynamics in microvascular complications in type 1 diabetes
-
Candido R, Allen TJ. Haemodynamics in microvascular complications in type 1 diabetes. Diabetes Metab Res Rev. 2002;18:286-304.
-
(2002)
Diabetes Metab Res Rev
, vol.18
, pp. 286-304
-
-
Candido, R.1
Allen, T.J.2
-
192
-
-
41749086422
-
Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus
-
Zanatta CM, Gerchman F, Burttet L, et al. Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;80:299-304.
-
(2008)
Diabetes Res Clin Pract
, vol.80
, pp. 299-304
-
-
Zanatta, C.M.1
Gerchman, F.2
Burttet, L.3
-
193
-
-
33845261609
-
Endothelin-A receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia
-
DOI 10.1681/ASN.2006060635
-
Chade AR, Krier JD, Textor SC, et al. Endothelin-a receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia. J Am Soc Nephrol. 2006;17: 3394-403. (Pubitemid 44865282)
-
(2006)
Journal of the American Society of Nephrology
, vol.17
, Issue.12
, pp. 3394-3403
-
-
Chade, A.R.1
Krier, J.D.2
Textor, S.C.3
Lerman, A.4
Lerman, L.O.5
-
194
-
-
33845979878
-
Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism
-
DOI 10.1681/ASN.2006030208
-
Sasser JM, Sullivan JC, Hobbs JL, et al. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol. 2007;18:143-54. (Pubitemid 46053429)
-
(2007)
Journal of the American Society of Nephrology
, vol.18
, Issue.1
, pp. 143-154
-
-
Sasser, J.M.1
Sullivan, J.C.2
Hobbs, J.L.3
Yamamoto, T.4
Pollock, D.M.5
Carmines, P.K.6
Pollock, J.S.7
-
195
-
-
11144267307
-
Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats
-
DOI 10.1097/01.fjc.0000166208.12297.8d
-
Thone-Reinke C, Simon K, Richter CM, et al. Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats. J Cardiovasc Pharmacol. 2004;44(Suppl 1):S76-9. (Pubitemid 40039648)
-
(2004)
Journal of Cardiovascular Pharmacology
, vol.44
, Issue.SUPPL. 1
-
-
Thone-Reinke, C.1
Simon, K.2
Richter, C.-M.3
Godes, M.4
Neumayer, H.-H.5
Thormahlen, D.6
Hocher, B.7
-
196
-
-
11144318752
-
Renal protective effect of YM598, a selective endothelin type A receptor antagonist
-
DOI 10.1097/01.fjc.0000166320.68753.e6
-
Sugimoto K, Fujimori A, Yuyama H, et al. Renal protective effect of YM598, a selective endothelin type A receptor antagonist. J Cardiovasc Pharmacol. 2004;44(Suppl 1):S451-4. (Pubitemid 40039736)
-
(2004)
Journal of Cardiovascular Pharmacology
, vol.44
, Issue.SUPPL. 1
-
-
Sugimoto, K.-I.1
Fujimori, A.2
Yuyama, H.3
Tahara, A.4
Fujimura, A.5
-
197
-
-
0141590203
-
Renal damage in the SHR/N-cp type 2 diabetes model: Comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker
-
DOI 10.1097/01.LAB.0000085188.23709.29
-
Gross ML, Ritz E, Schoof A, et al. Renal damage in the SHR/N-cp type 2 diabetes model: Comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker. Lab Investig. 2003;83:1267-77. (Pubitemid 37140311)
-
(2003)
Laboratory Investigation
, vol.83
, Issue.9
, pp. 1267-1277
-
-
Gross, M.-L.1
Ritz, E.2
Schoof, A.3
Helmke, B.4
Parkman, A.5
Tulp, O.6
Munter, K.7
Amann, K.8
-
198
-
-
0344154548
-
Nephroprotective Effect of Bosentan in Diabetic Rats
-
DOI 10.1097/00005344-200312000-00009
-
Cosenzi A, Bernobich E, Trevisan R, et al. Nephroprotective effect of bosentan in diabetic rats. J Cardiovasc Pharmacol. 2003;42:752-6. (Pubitemid 37467097)
-
(2003)
Journal of Cardiovascular Pharmacology
, vol.42
, Issue.6
, pp. 752-756
-
-
Cosenzi, A.1
Bernobich, E.2
Trevisan, R.3
Milutinovic, N.4
Borri, A.5
Bellini, G.6
-
199
-
-
1542564748
-
ABT-627 a selective eta-receptor antagonist reduces proteinuria in patients with diabetes mellitus. In
-
Utrecht, Netherlands: Elinkwijk BV
-
Honing ML, Hijmering ML, Ballard DE, et al. ABT-627, a selective eta-receptor antagonist, reduces proteinuria in patients with diabetes mellitus. In: Regulation of Vascular Tone in Humans by Endothelium-Derived Mediators. Utrecht, Netherlands: Elinkwijk BV; 2000;89-102
-
(2000)
Regulation of Vascular Tone in Humans by Endothelium-Derived Mediators
, pp. 89-102
-
-
Honing, M.L.1
Hijmering, M.L.2
Ballard, D.E.3
-
200
-
-
33750243479
-
The ETA-selective antagonist SPP301 on top of standard treatment reduces urinary albumin excretion rate in patients with diabetic nephropathy
-
Wenzel RR et al. The ETA-selective antagonist SPP301 on top of standard treatment reduces urinary albumin excretion rate in patients with diabetic nephropathy. ASN Renal Week 2005.
-
(2005)
ASN Renal Week
-
-
Wenzel, R.R.1
-
202
-
-
0035834748
-
Amides are novel protein modifications formed by physiological sugars
-
Glomb MA, Pfahler C. Amides are novel protein modifications formed by physiological sugars. J Biol Chem. 2001;276:41638-47.
-
(2001)
J Biol Chem
, vol.276
, pp. 41638-47
-
-
Glomb, M.A.1
Pfahler, C.2
-
203
-
-
0023950461
-
Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
-
Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315-21.
-
(1988)
N Engl J Med
, vol.318
, pp. 1315-21
-
-
Brownlee, M.1
Cerami, A.2
Vlassara, H.3
-
205
-
-
0032857820
-
Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II)
-
DOI 10.1016/S0197-2456(99)00024-0, PII S0197245699000240
-
Freedman BI, Wuerth JP, Cartwright K, et al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials. 1999;20:493-510. (Pubitemid 29460926)
-
(1999)
Controlled Clinical Trials
, vol.20
, Issue.5
, pp. 493-510
-
-
Freedman, B.I.1
Wuerth, J.-P.2
Cartwright, K.3
Bain, R.P.4
Dippe, S.5
Hershon, K.6
Mooradian, A.D.7
Spinowitz, B.S.8
-
206
-
-
12144257117
-
Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease
-
Williams ME. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease. Curr Diab Rep. 2004;4:441-6. (Pubitemid 40104220)
-
(2004)
Current Diabetes Reports
, vol.4
, Issue.6
, pp. 441-446
-
-
Williams, M.E.1
-
207
-
-
12144263911
-
A phase 2 clinical trial of pyridoxamine (Pyridorin) in type 1 and type 2 diabetic patients with overt nephropathy (PYR-206
-
Williams ME. A phase 2 clinical trial of pyridoxamine (Pyridorin) in type 1 and type 2 diabetic patients with overt nephropathy (PYR-206). J Am Soc Nephrol. 2003;2003:7A.
-
(2003)
J Am Soc Nephrol
, vol.2003
-
-
Williams, M.E.1
-
208
-
-
0035949502
-
Improved arterial compliance by a novel advanced glycation end-product crosslink breaker
-
Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 2001;104:1464-70. (Pubitemid 32917336)
-
(2001)
Circulation
, vol.104
, Issue.13
, pp. 1464-1470
-
-
Kass, D.A.1
Shapiro, E.P.2
Kawaguchi, M.3
Capriotti, A.R.4
Scuteri, A.5
DeGroof, R.C.6
Lakatta, E.G.7
-
209
-
-
0142121508
-
Therapeutic potential of breakers of advanced glycation end product-protein crosslinks
-
DOI 10.1016/j.abb.2003.08.016
-
Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys. 2003;419:89-96. (Pubitemid 37272162)
-
(2003)
Archives of Biochemistry and Biophysics
, vol.419
, Issue.1
, pp. 89-96
-
-
Vasan, S.1
Foiles, P.2
Founds, H.3
-
210
-
-
78149359262
-
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial
-
de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial. Lancet. 2010;376:1543-51.
-
(2010)
Lancet
, vol.376
, pp. 1543-51
-
-
De Zeeuw, D.1
Agarwal, R.2
Amdahl, M.3
-
211
-
-
79954582442
-
Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD
-
Pergola PE, Krauth M, Huff JW, et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol. 2011;33:469-76.
-
(2011)
Am J Nephrol
, vol.33
, pp. 469-76
-
-
Pergola, P.E.1
Krauth, M.2
Huff, J.W.3
-
212
-
-
79960855656
-
Bardoxolone methyl and kidney function in CKD with type 2 diabetes
-
Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011.
-
(2011)
N Engl J Med
-
-
Pergola, P.E.1
Raskin, P.2
Toto, R.D.3
-
213
-
-
33845996154
-
Standards of medical care in diabetes-2007
-
Standards of medical care in diabetes-2007. Diabetes Care. 2007;30 (Suppl 1):S4-S41.
-
(2007)
Diabetes Care
, vol.30
, Issue.SUPPL. 1
-
-
|